您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Atazanavir Sulfate(Latazanavir,Zrivada,Reyataz,BMS232632)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Atazanavir Sulfate(Latazanavir,Zrivada,Reyataz,BMS232632)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Atazanavir Sulfate(Latazanavir,Zrivada,Reyataz,BMS232632)图片
CAS NO:229975-97-7
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
Atazanavir Sulfate (also known as Latazanavir, Zrivada, Reyataz, BMS-232632), the sulfate salt form of atazanavir, is a HIV protease inhibitor (PI) for HIV/AIDs treatment with Ki of 2.66 nM in a cell-free assay. Like other antiretrovirals, it is used to treat infection of HIV/human immunodeficiency virus. Atazanavir is distinguished from other PIs in that it can be administered once-daily and has lesser effects on the patient's lipid profile. Like other protease inhibitors, it is used only in combination with other HIV medications.
理化性质和储存条件
Molecular Weight (MW)802.93
FormulaC38H52N6O7.H2SO4
CAS No.229975-97-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 104 mg/mL (129.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL
SynonymsBMS-232632; Atazanavir sulfate; BMS232632; BMS 232632

Chemical Name: 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt)

InChi Key: DQSGVVGOPRWTKI-QVFAWCHISA-N

InChi Code: InChI=1S/C38H52N6O7.H2O4S/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28;1-5(2,3)4/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47);(H2,1,2,3,4)/t29-,30-,31+,32+;/m0./s1

SMILES Code: O=C(OC)N[C@@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C)(C)C)NC(OC)=O)=O)=O.O=S(O)(O)=O

实验参考方法
In Vitro

In vitro activity: Atazanavir inhibits the proteolytic cleavage of the viral gag precursor p55 polyprotein with IC50 of ~47 nM in virus-infected H9 cells. Atazanavir exhibits potent antiviral activity with EC50 of 3.89 nM in RF/MT-2 strains. Atazanavir is shown to be an inhibitor of bilirubin glucuronidation with IC50 of 2.4 μM. Atazanavir inhibits recombinant UGT1A1 with Ki of 1.9 μM. Atazanavir inhibits cell growth in U251, T98G, and LN229 glioblastoma cell lines, with strikingly increased GRP78 and CHOP protein levels. Atazanavir causes a prominent increase of polyubiquitinated proteins of various different sizes in U251 glioblastoma cells. Atazanavir also inhibits human 20S proteasome with IC50 of 26 μM. Atazanavir (30 μM) changes the magnitudes of ER stress and UPR gene expression in HepG2 cells. Atazanavir (30 mM) causes a 2.5-fold increase in immunoreactive P-gp expression with decreased intracellular Rh123 in LS180V cells.


Kinase Assay: To determine the inhibition constants (Ki) for each Prt inhibitor, purified HIV-1 RF wild-type Prt (2.5 nM) is incubated at 37 ℃ with 1 μM to 15 μM fluorogenic substrate in reaction buffer (1 M NaCl, 1 mM EDTA, 0.1 M sodium acetate [pH 5.5], 0.1% polyethylene glycol 8000) in the presence or absence of Atazanavir. Cleavage of the substrate is quantified by measuring an increase in fluorescent emission at 490 nM after excitation at 340 nM using a Cytofluor 4000. Reactions are carried out using 1.36 μM, 1.66 μM, 2.1 μM, 3.0 μM, 5.0 μM, or 15 μM substrate in the presence of five concentrations of Atazanavir (1.25 nM to 25 nM). Substrate cleavage is monitored at 5-min intervals for 30 min. Cleavage rates are then determined for each sample at early time points in the reaction, and Ki values are determined from the slopes of the resulting Michaelis-Menten plots.


Cell Assay: To determine cytotoxicity, host cells are incubated in the presence of serially diluted Atazanavir for 6 days and cell viability is quantitated using an XTT[2,3-bis(2-methoxy-4-nitro-5-sulfophenyl-2H-tetrazolium-5-carboxanilide] assay to calculate the 50% cytotoxic concentrations (CC50s). To assess the effect of human serum proteins on antiviral activity, the 10% fetal calf serum normally used for assays is replaced with 40% adult human serum or 1 mg of α1-acid glycoprotein/mL.

In Vivo
Animal model
Formulation & Dosage
References

Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9; Cancer Res. 2007 Nov 15;67(22):10920-8.

生物活性




Inhibition of HIV-1 gag processing by BMS-232632. Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.

Analysis of two-drug combinations using the MacSynergy program to compare drug interactions of BMS-232632 with RT inhibitors d4T (A), ddI (B), AZT (C), and 3TC (D). Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.

Analysis of two-drug combinations using the MacSynergy program to compare drug interactions of BMS-232632 with Prt inhibitors RTV (A), SQV (B), IDV (C), NFV (D), and APV (E). Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.